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Abstract
Background: Recommendations for diphtheria immunization are to apply an effective primary immunization in
infancy and to maintain immunity throughout life. Immunity against diphtheria depends primarily on antibody to
the diphtheria toxin. This study evaluated the seroprevalence of IgG diphtheria antitoxin in sera of healthy children,
adolescents and adults in Poland.
Methods: A total of 1387 serum samples collected between 2010 and 2012 from individuals with ages ranging
from 1 month to 85 years were investigated. Antibody concentrations were measured with an enzyme-linked
immunosorbent assay (Anti-Diphtheria Toxoid ELISA IgG, Euroimmun, Germany).
Results: The results showed that among 1387 individuals examined, 547 (39.4%) had anti-diphtheria toxoid IgG
antibody levels below 0.1 IU/ml (36.9% ≤18 years and 40.5% >18 years old, respectively). The 212 (50.8%) children and
542 (55.9%) adults showed only basic protection (0.1-1.0 IU/ml) and need immediate booster. High levels of
anti-diphtheria toxoid IgG antibodies (>1.0 IU/ml) were found more often in children and adolescent (12.2%) than in
adults (3.6%) and this was statistically significant (P < 0.05). The proportion of seronegatives (< 0.1 IU/ml) in children
below 2 years old, adolescents and young adults to 25 years old decreased from 53.5% to 17.4%. However, in older
individuals the seronegative proportion tended to increase with age, from 22.7% in adults (26–30 years old) to 67.1% in
subjects > 60 years old. Characteristically, in individuals > 40 years old high levels of anti-diphtheria toxoid IgG antibodies
(>1.0 IU/ml) were not seen. There were no statistically significant differences in results in relation to gender.
Conclusions: The present study showed inadequate immunity levels to diphtheria amongst the Polish population,
especially in adults > 40 years old and children ≤ 2 years old. To prevent reemergence of diphtheria an information
campaign reminding people about recommendations concerning diphtheria booster vaccination in adults should be
conducted. Moreover, the immunogenicity of the DTP vaccine used in Poland should be verified.
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Background
Diphtheria is a severe and potentially fatal disease caused
by toxin-producing strains of Corynebacterium diphtheriae,
Corynebacterium ulcerans and Corynebacterium pseudotu-
berculosis. Before the introduction of active vaccination in
1940s, diphtheria was endemic in most European countries
[1]. Currently, the disease appears to be well controlled in
developed countries but is still endemic in Africa, Asia and
Eastern Europe [2]. Humoral immunity against diphtheria
depends primarily on formation of specific IgG antibodies
to diphtheria toxin, which may be induced by natural infec-
tion, passive or active immunization. As diphtheria has be-
come rarer, opportunities for acquisition or reinforcing
natural immunity have also been reduced [3,4]. In most
European countries diphtheria vaccine is included in the
recommended vaccination schedule. In Poland the diph-
theria vaccination schedule comprises 7 doses administered
at 2 months, 3–4 months, 5–6 months, 16–18 months and
then 6, 14 and 19 years. According to World Health
Organization data, more than 95% of children are fully vac-
cinated against the disease in Poland. However, the level of
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antibodies decreases with time and adults may again be-
come susceptible to diphtheria due to reduced opportun-
ities for boosting through subclinical infections. A large
pool of susceptible persons creates an epidemic potential,
as demonstrated by the last diphtheria epidemic that oc-
curred in the early 1990s in the countries of the former
Soviet Union when more than 50 000 cases were recorded
at the peak of the epidemic. During this epidemic adoles-
cents and adults were mainly affected, most of whom
would have been previously vaccinated [4-7]. Moreover,
during the last decade the number of diphtheria cases due
to C. ulcerans has increased in Europe. For example, 63%
of toxigenic corynebacteria isolated in France in 2002–2008
and in United Kingdom in 2000–2009 were C. ulcerans.
The reservoir hosts of this species are domestic cats and
dogs [8,9].
In Poland the last diphtheria case was recorded in
2000 and the previous 9 cases were recorded in 1996
[10]. In the present study we determined the immune
status against diphtheria in different age groups of the
population after a period of over 10 years with no cases
of diphtheria in Poland.
Methods
Study population
A total of 1387 serum samples were collected to examine
the specific anti-diphtheria toxoid antibody levels. Writ-
ten informed consent was obtained from participants,
parents or guardians. The serum bank comprised sam-
ples collected between 2010 and 2012, from individuals
living in different regions of Poland aged from 1 month
to 85 years (median, 26 years). Samples from the group
aged 0–18 years (n = 417) were residual sera from diag-
nostic laboratories, whereas samples from the adult
population (n = 970) included residual sera from diagnos-
tic laboratories (n = 260) and additionally from routine
screening tests of healthy blood donors (n = 390), forest
workers (n = 122) and pregnant women (n = 198). Diph-
theria vaccination history of the tested individuals was
not available. Data on gender were available from 1047
individuals (544 females and 503 males). Precise data on
age were not obtained from forest workers and most of
the blood donors.
Determination of diphtheria toxoid antibody levels
Diphtheria toxoid IgG-specific antibody levels were de-
termined using a commercial ELISA Anti-Diphtheria
Toxoid ELISA IgG (Euroimmun, Germany) selected in
previous studies as the most reliable of those anti-
diphtheria IgG assays tested [11]. For quantitative
evaluation four ready-to-use calibrators - Calibrator 1
(2 IU/ml), Calibrator 2 (1 IU/ml), Calibrator 3 (0.1 IU/
ml), Calibrator 4 (0.01 IU/ml) and two control sera (one
positive and one negative) were provided in the kit.
The concentrations of the of anti-diphtheria toxoid anti-
bodies in serum samples were determined using a stand-
ard curve. For the calculation of the standard curve the
OD (optical density) of each Calibrator (y-axis, linear) was
plotted against the concentration (x-axis, logarithmic)
using Excel (Microsoft). The four Calibrators were cali-
brated in IU/ml against the International Standard for
Diphtheria Antitoxin NIBSC 00/496. The initial dilution
of test sera was 1:101. Samples which showed concentra-
tions above the highest standard were further diluted. Re-
sults of samples with higher predilution were multiplied
by the dilution factor. Manufacturer recommended div-
ision of the results into five groups: <0.1 IU/ml (indicating
immediate basic immunisation), 0.1-1.0 IU/ml (immediate
booster), > 1.0-1.5 IU/ml (booster after 5 years), > 1.5-
2.0 IU/ml (booster after 7 years) and > 2.0 IU/ml (booster
after 10 years).
Statistical analysis
The study population was divided into ten age groups:
0–2, 3–5, 6–13, 14–18, 19–25, 26–30, 31–40, 41–50,
51–60 and > 60 years. The arithmetic mean titres, stand-
ard deviations and geometric mean titres were calculated
using Excel. The statistical significance of the differences
was analyzed by Fisher’s exact probability test with Yates’
correction when at least one of the calculated figures
was <5. A P-value < 0.05 was considered significant.
The studies were approved by Bioethics Committee of
National Institute of Public Health – National Institute
of Hygiene (reference number 2/2013).
Results
The distribution of antibodies, arithmetic and geometric
mean titres and other statistical parameters in children
and adults are presented in Table 1. Among 1387 individ-
uals examined, 547 (39.4%) had levels of anti-diphtheria
toxoid IgG antibodies below 0.1 IU/ml (36.9% ≤ 18 years
and 40.5% >18 years old, respectively). The 212 (50.8%)
children and 542 (55.9%) adults showed only basic protec-
tion (0.1-1.0 IU/ml) and require immediate immunisation.
In general, the difference in the number of seronegatives
and low positives (0.1-1.0 IU/ml) between individuals ≤ 18
years old and adults was not statistically significant (P >
0.05). However, high levels of anti-diphteria toxoid IgG
antibodies (>1.0 IU/ml) were more often found in children
and adolescent (12.2%) than in adults (3.6%) (P < 0.05) and
this was statistically significant. The geometric mean titre
(GMT) was low, both in children (0.141 IU/ml) and in
adults (0.102 IU/ml). There was no statistically significant
difference in diphtheria antibody levels between males and
females (P > 0.05).
Data presented in the Table 2 show in more detail the
distribution of anti-diphtheria toxoid IgG titres in healthy
individuals from different age groups. The proportion of
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seronegatives (< 0.1 IU/ml) in children, adolescents and
young adults up to 25 years old appears to decrease from
53.5% to 17.4%. However, in older individuals the sero-
negative proportion tended to increase with age, from
22.7% in adults aged 26–30 years to 67.1% in subjects >
60 years old. Characteristically, in individuals > 40 years
old high levels of anti-diphteria toxoid IgG antibodies
(>1.0 IU/ml) were not seen.
A similar picture is seen in Figures 1 and 2, which show
the geometric mean concentration of anti-diphtheria tox-
oid IgG antibodies and percentage of subjects with anti-
diphtheria toxoid antibody levels ≥ 0.1 IU/ml according
to age groups, respectively. The effects of the each
booster dose are clearly visible, causing the maximum
protection level in individuals aged 19–25 years (GMT=
0.274 IU/ml). In older age groups we can see the decrease
of GMT values as well as decrease of the percentage of
subjects with protective levels of anti-diphtheria toxoid
IgG antibodies. The most notable observation is the dra-
matic decrease of protection in individuals > 40 years old.
Discussion
Although diphtheria has occurred sporadically in Western
Europe, the risk of importation of the disease from en-
demic regions is increasing together with the increase in
the risk of infection via mass tourism to diphtheria en-
demic countries. Moreover, domestic animals, such as cats
and dogs, were identified as a new source of human infec-
tions of diphtheria toxin producing C. ulcerans [1,8]. For
these reasons a protective level of diphtheria toxin anti-
bodies should be maintained in populations.
In this study the overall proportion of susceptible per-
sons was 39.4%. This is of great concern as such a high
percentage without a protective level of anti-diphtheria
antibodies creates an epidemic potential. WHO outlined
that to achieve sufficient herd immunity a minimum im-
munity rate of 90% in children and 75% in adults is re-
quired [12]. The DTP (the diphtheria-tetanus-pertussis
vaccine) vaccination coverage in children in Poland has
been 99% since 2002, and in previous years it was ≥ 95%
(http:/apps.who.int/gho/data/node.main.A827?lang=en).
Despite the fact that > 95% children in Poland have re-
ceived routine primary vaccination with three doses of
DTP and one booster within the first 2 years of life only
46.5% of them demonstrated anti-diphtheria antibodies
level ≥ 0.1 IU/ml. The low geometric mean in population
of children ≥ 2 years old might be related to the lack of
adherence to the vaccination schedule. We have not
verified this hypothesis as we have no data concerning
the vaccination calendar for each tested individual.
Nevertheless, this hypothesis may be unlikely because
CDC states that interruption of the recommended
schedule or delay of subsequent doses does not reduce
the response to the vaccine when the series is finally
completed [13].
The antibody level in the Polish population increased
with each booster dose and achieved the highest level in
young adults (19–25 years) after the last booster adminis-
tered at age 19 years. It is worth underlining that overall
Table 1 Distribution of seroprotection against diphtheria
in the Polish population according to age group
Age groups ≤18 years >18 years Total
Number of persons 417 970 1387
Titre < 0.1 IU/ml 154 (36.9%) 393 (40.5%) 547 (39.4%)
Titre 0.1-1.0 IU/ml 212 (50.8%) 542 (55.9%) 754 (54.4%)
Titre >1-1.5 IU/ml 30 (7.2%) 26 (2.7%) 56 (4.0%)
Titre >1.5-2 IU/ml 18 (4.3%) 6 (0.6%) 24 (1.7%)
Titre > 2.0 IU/ml 3 (0.7%) 3 (0.3%) 6 (0.4%)
Arithmetic mean titre (IU/ml) 0.409 0.274 0.310
Standard deviation (IU/ml) 0.559 0.324 0.414
Geometric mean titre (IU/ml) 0.141 0.102 0.108
Minimum (IU/ml) 0.001 0.001 0.001
Maximum (IU/ml) 4.480 1.740 4.480
Median (IU/ml) 0.210 0.150 0.160





Number (percentage) of sera with level of anti-diphtheria antibodies:
<0.1 IU/ml 0.1-1.0 IU/ml >1-1.5 IU/ml >1.5-2.0 IU/ml >2.0 IU/ml
0-2 114 61 (53.5) 38 (33.0) 10 (8.8) 4 (3.5) 1 (0.8)
3-5 100 36 (36.0 49 (49.0) 7 (7.0) 7 (7.0) 1 (1.0)
6-13 133 41 (30.8) 77 (57.9) 9 (6.8) 5 (3.8) 1 (0,8)
14-18 70 16 (22.9) 48 (68.6) 4 (5.7) 2 (2.9) -
19-25 69 12 (17.4) 52 (75.4) 5 (7.2) - -
26-30 110 25 (22.7) 80 (72.7) 3 (2.7) 2 (1.8) -
31-40 145 34 (23.4) 103 (71.0) 6 (4.1) 1 (0.7) 1 (0.7)
41-50 80 51 (63.8) 29 (36.2) - - -
51-60 70 46 (65.7) 24 (34.3) - - -
>60 73 49 (67.1) 24 (32.9) - - -
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the proportion of persons with a high level of anti-
diphteria toxoid IgG antibodies (>1.0 IU/ml), which con-
fers long-term protection, was only 6.1%. These results
differ significantly from those obtained in a previous study
concerning the prevalence of diphtheria immunity in the
Polish population conducted in 1990s by Walory et al. [3].
These authors showed that 23% individuals examined
were seronegative, 64% showed basic protection (0.1-
1.0 IU/ml) and 13% were highly protected (>1.0 IU/ml).
The higher level of diphtheria antitoxin antibodies in the
Polish population in the 1990s may have been maintained
by reinforcing natural immunity and boosting through
subclinical infections, as in 1990s and earlier, diphtheria
was a quite common disease in Poland. Such an explan-
ation is supported by the observation in Latvia where
diphtheria is endemic and the prevalence of antibodies to
diphtheria toxin is high in all age groups of the population
(investigated using a commercial ELISA kit) [14].
Ohuabunwo et al. [15] revealed that individuals who
received a booster dose of an anti-diphtheria vaccine with
higher-antigen concentration DT as oppose to the lower-
antigen concentration dT had higher diphtheria toxin
antibody levels. According to Polish recommendations
children up to 6 years old received DTP or DT vaccine
containing ≥30 IU of diphtheria toxoid, whereas teen-
agers and adults received dT vaccine containing ≥ 0.5 IU
of diphtheria toxoid. Administration of the higher-antigen
concentration anti-diphtheria vaccine to children did
not give the expected higher anti-diphtheria antibodies
levels. There remains a question as to whether adminis-
tration of DT to teenagers and adults instead of dT would
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Figure 2 Percentage of subjects with diphtheria toxoid antibody levels ≥0.1 IU/ml in the Polish population according to the
age groups.
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levels in these persons. This problem should be investi-
gated in the near future.
Studies concerning seroepidemiology of diphtheria in
Western Europe revealed that the proportion with serum
antibodies to diphtheria toxin rises with age in children,
which is in agreement with our findings [16]. But in our
studies <50% children in age 0–2 years old had protective
level of antibodies whereas Edmunds et al. [16] showed
that >90% of 1 year olds were seropositive (various tests
were used, such as ELISA, DELFIA, ToBI and the Vero
cell neutralization test). A low proportion of seropositive
children was also identified in the Czech Republic (using
the Vero cell neutralization test) [14]. Our results together
with results obtained for Czech population support the
opinion of Chironna et al. [17], that basic immunization
without booster doses may result in unsatisfactory protec-
tion among children. The differences in the proportion of
seropositive children may be a result of the application of
different vaccines. Poland is the only European country
which uses the DTP vaccine containing a whole-cell per-
tussis component (DTwP). The acellular vaccine (DTaP) is
also available, but is not refunded by the government
therefore the overwhelming majority of children are vacci-
nated using the DTwP. It is documented in the scientific
literature that antibody responses to all antigens in DTwP
vaccines can be lower compared to DTaP vaccines [18,19].
However, some authors showed that antibody response to
the diphtheria toxoid antigen is similar in DTwP and
DTaP vaccines [20-23]. Considering the above discrepan-
cies as well as the results of our study, it would be prudent
to reevaluate the immunogenicity of the DTwP vaccine
used in Poland in comparison to DTaP vaccines registered
in Poland. Results of this evaluation may lead to changes
in recommendations for immunization which could im-
prove diphtheria immunity in the Polish population and
reduce the risk of diphtheria infection.
In all European countries where diphtheria seropreva-
lence studies were conducted, including Poland, the level
of antibodies to diphtheria toxin decreases significantly
in persons above 40 years old [14,16,24-29]. The most
drastic decrease was observed in Poland (this study),
Spain and Ireland, reaching > 67% of seronegative indi-
viduals [14,25].
No significant sex-related differences in the proportion
of seropositive individuals were identified in Poland, al-
though, in some countries marked sex-related differ-
ences were observed with higher number of seropositive
males. This is probably due to the fact that in those
countries military recruits had been vaccinated against
diphtheria [26-29].
Measuring the amount of serum antibodies against diph-
theria toxin in individuals is the only way to survey the level
of protection in a community. Even though the use of dif-
ferent methods and test kits for determination of the anti-
diphtheria antibodies level may influence the results ob-
tained [11], the comparison of seroprevalence in various
European countries clearly demonstrate that a high per-
centage of adults is not protected against diphtheria. In
Poland, similar to several other European countries, booster
doses every 10 years in adults are recommended. However,
it is difficult to monitor vaccination coverage in adults and,
as suggested by our results, diphtheria booster vaccination
in adults is uncommon. A national information campaign
should be organized to inform the public about the import-
ance of following vaccination recommendations and to per-
suade the public that diphtheria vaccines are useful not
only for children but also for adults. A special effort should
be made to remind health-care workers, especially general
practitioners, about the importance of diphtheria booster
vaccinations every 10 years. Adaptation of vaccination strat-
egies should also be considered such that every 10 year a
general recommendation would be issued (e.g., at age 40,
50, 60, etc.). This would help patients and doctors remem-
ber and monitor booster doses.
Despite the high proportion of seronegative individuals
in Polish population, diphtheria cases have not been re-
corded for over 10 years. It could be argued that toxi-
genic corynebacteria do not circulate in the population.
But it must be kept in mind that the disease could be
imported from endemic regions and cause an outbreak
in a susceptible community.
Conclusions
This study showed that there is insufficient herd immunity
to diphtheria in the Polish population which could potential
lead to an epidemic. Before the introduction of diphtheria
vaccination, diphtheria was predominantly known as a
childhood infection. Currently the disease affects mainly
adults [1,8,9]. Due to the low levels of anti-diphtheria anti-
bodies in persons > 40 years old, the development of tour-
ism to diphtheria endemic regions and the newly identified
source of infection, i.e., domestic cats and dogs, it seems
reasonable to carry out a publicity campaign regarding rec-
ommendations for diphtheria booster vaccination in adults.
Special attention should be paid to travelers and persons
taking care of cats and dogs. Moreover, due to the low pro-
portion of seropositives found in children ≤ 2 years old the
immunogenicity of the DTP vaccine used in Poland should
be verified. Full protection in the highest possible propor-
tion of the population should help to avoid re-emergence
of this serious, potentially fatal infectious disease.
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